AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The company strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, in addition to products and services across its Allergan Aesthetics portfolio.

For more information about AbbVie, please visit us visit www.abbvie.co.uk. Follow us on Twitter, YouTube.

Amgen

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realise new science’s promise by bringing safe, effective medicines from the lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to help improve people’s lives.

For more information about Amgen, our pioneering science and our vital medicines, visit www.amgen.com

Biogen

Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations for people living with serious neurological diseases as well as related therapeutic adjacencies.  Biogen has a portfolio of medicines and potential therapies across neurology, neuropsychiatry, specialised immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

​​​​​​​To learn more, please visit www.biogen.uk.com,  www.biogen.ie.

Bristol Myers Squibb

Bristol Myers Squibb Pharmaceuticals Ltd (BMS) is a global BioPharma company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines help millions of patients in their fight against cancer, cardiovascular disease, diabetes, hepatitis B, HIV, rheumatoid arthritis and psychiatric disorders. BMS has a significant presence in the UK, with sites in Uxbridge and the North West of England, and a comprehensive clinical trials programme, in all stages of development, taking place across the country.

See www.b-ms.co.uk for more information.

Incyte

Since Incyte’s start in 2002 with a small number of scientists, chemists and biologists in Wilmington, Delaware, we have grown into a global organisation with a robust portfolio of treatments across Oncology and Inflammation & Autoimmunity. Today this passion for innovation is stronger than ever with a team of more than 2,000 employees who believe every challenge we face is a chance for a breakthrough and an opportunity to find meaningful solutions for patients. Focusing in areas where we can have a significant impact, regardless of the disease or size of the patient population, has resulted in a strong heritage of Incyte-discovered, first-in-class medicines for patients who previously had limited treatment options.

Please visit incytebiosciences.uk to find out more.

Gilead

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead’s portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, hepatitis, serious respiratory and cardiovascular conditions, cancer and inflammation. Gilead was founded in 1987 in Foster City, California and has become a leading biopharmaceutical company with a rapidly expanding product portfolio and over 14,000 employees over 35 countries.

Please visit www.gilead.co.uk for more information.

J&J Innovative Medicine

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at janssen.com/uk/johnson-johnson-innovative-medicine.

Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers — through medicines and information — for some of the world’s most urgent medical needs.

Lilly has a long heritage in the UK, opening its first facility outside North America in London in 1934. Today Lilly has around 700 talented employees in the UK working across two sites in roles such as regulatory affairs, medical affairs, marketing, and communications.

Additional information about Lilly is available at www.lilly.co.uk.

MSD

MSD believe the most important thing it makes is a difference. Through its prescription medicines, vaccines, biologic therapies, consumer care and animal health products, MSD works with customers and operates in more than 140 countries to bring innovative healthcare solutions to those who need them the most. MSD also demonstrate its commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships. For more information, visit www.msd-uk.co.uk.

MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A.

Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex’s global headquarters is now located in Boston’s Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry’s top places to work, including 11 consecutive years on Science magazine’s Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign.

Please visit www.vrtxpharma.co.uk to find out more.